Inclusion Criteria:  Patients must provide written consent to cooperate in this study before the start of treatment with Kesimpta  Patients using Kesimpta for the first time for the following indication Indication: prevention of relapses and and prevention of physical disability progression in the following patients  Relapsing-remitting MS Active SPMS  Exclusion Criteria:  Patients with a history of treatment with a drug containing the same ingredient as Kesimpta (investigational drug or post-marketing clinical study drug) Patients with a history of hypersensitivity to any of the Kesimpta ingredients